

Special Issue

Advances in Research on HIV Drug Resistance and Other Determinants of Treatment Success

Message from the Guest Editor

The field of antiretroviral therapy has been steadily evolving in recent years. New potent antiretroviral drugs have allowed the use of two drugs-combinations for both naïve and treatment-experienced patients, alongside standard three-drug antiretroviral therapies. However, antiretroviral drugs-resistance and other viro-immunological factors (such as viral reservoir, viral subtypes, history of virological failure and therapeutic lines) can still play a role in influencing the risk of virological failure and therapy discontinuation. Moreover, since randomized trials typically exclude patients with those risk factors, clinicians involved in HIV field have few or no clues to safely optimize current antiretroviral therapies in a large proportion of patients with a long history of antiretroviral exposure (especially with previous virological failures), experiencing the burden of age-related, non-communicable diseases, toxicities from antiretroviral regimens and drug-drug interactions.

Guest Editor

Dr. Alberto Borghetti

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC
Malattie Infettive, 00168 Rome, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/115822

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).